Financiado en parte por Pfizer
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly
Chiloiro S, Frara S, Gagliardi I, Bianchi A, Giampietro A, Medici M, Allora A, di Filippo L, Ambrosio MR, Pontecorvi A, Zatelli MC, De Marinis L, Giustina A
The Journal of clinical endocrinology and metabolism · 18 citas
Etiquetas de revisión
Vínculos de autores con la industriaFinanciado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Pfizer
- Autores
- Al menos un autor declara un vínculo económico con la industria
- Subvenciones
- Pfizer (56843615).)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-08-22 · J Clin Endocrinol Metab · vol. 109 · número 1 · págs. e58–e68
- Editorial
- Oxford University Press
- Citado
- 27 citas · más que el 95% de estudios similares · 3.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 66 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Pituitary Gland Disorders and Treatments · Vitamin K Research Studies · Vitamin D Research Studies
- Palabras clave
- Medicine, Interquartile range, Acromegaly, Internal medicine, Retrospective cohort study, Odds ratio, Osteoporosis, Complication, Cholecalciferol, Concomitant, Gastroenterology, Logistic regression, Vitamin D and neurology, Surgery, Hormone, Growth hormone
- MeSH
- humans, acromegaly, spinal fractures, cholecalciferol, retrospective studies, bone density
13 autores
- Sabrina Chiloiro🇮🇹Università Cattolica del Sacro Cuore; Agostino Gemelli University Polyclinic
- Stefano Frara🇮🇹Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
- Irene Gagliardi🇮🇹University of Ferrara
- Antonio Bianchi🇮🇹Università Cattolica del Sacro Cuore; Agostino Gemelli University Polyclinic
- Antonella Giampietro🇮🇹Università Cattolica del Sacro Cuore; Agostino Gemelli University Polyclinic
- Margherita Medici🇮🇹University of Ferrara
- Agnese Allora🇮🇹Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
- Luigi di Filippo🇮🇹Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
- Maria Rosaria Ambrosio🇮🇹University of Ferrara
- Alfredo Pontecorvi🇮🇹Università Cattolica del Sacro Cuore; Agostino Gemelli University Polyclinic
- Maria Chiara Zatelli🇮🇹University of Ferrara
- Laura De Marinis🇮🇹Università Cattolica del Sacro Cuore; Agostino Gemelli University Polyclinic
- Andrea Giustina🇮🇹 · autor de correspondenciaVita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Skeletal fragility is observed in 30% to 60% of acromegaly patients, representing an emerging complication of the disease that increases disability. Despite several studies having investigated the clinical and hormonal prognostic factors for the occurrence of vertebral fractures (VFs) in acromegaly, very few data are available on their prevention/treatment including the effect of vitamin D (VD) supplementation, which has been reported to have a fracture-protective effect in several studies in patients with osteoporosis.
Objective
We aimed to investigate the role of cholecalciferol (D3) supplementation in the prevention of incident VFs (i-VFs) in acromegaly.
Methods
A longitudinal, retrospective and multicenter study was performed on 61 acromegaly patients treated and untreated with D3 supplementation.
Results
Twenty-six patients were treated with D3 supplementation according to clinical guidelines. The median D3 weekly dosage was 8500 IU (interquartile range [IQR]: 3900). The median duration of D3 supplementation was 94 months (IQR: 38). At last follow-up, i-VFs were diagnosed in 14 patients (23%). I-VFs were less prevalent in patients on D3 supplementation (14.3% of cases) compared to patients not treated with D3 (85.7%; P = .02). The final level of serum V25OH-D was significantly lower in patients who developed i-VFs (28.6 ng/mL, IQR: 4.1) compared to patients who did not develop i-VFs (34.2 ng/mL, IQR: 9.6; P = .05). The logistic regression confirmed the protective role of D3 supplementation on the occurrence of i-VFs (odds ratio: 0.16; 95% CI, 0.03-0.79; P = .01).
Conclusion
It is likely that D3 supplementation could lead to a reduction in i-VFs in acromegaly.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.